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ABSTRACT 
Valproic acid (VPA) is a broad spectrum antiepileptic agent used in the treatment of absence, myoclonic, partial and tonic clonic seizure and also 
used in the treatment of bipolar disorder. Although VPA, a proven anticonvulsant agent thought to have relatively few side-effects, has been referred 
as the third most common xenobiotic suspected of causing death due to liver injury. VPA-induced hepatotoxicity can be identified through an 
abnormal liver function test mainly an abnormal elevation in hepatic enzymes which is called transaminitis. Here we report a case of 21 y old female 
presented with transaminitis which occurred after 3 y of taking VPA that was started in view of here seizure disorder. The hepatic enzyme levels 
came down once VPA was stopped and appropriate treatment measures using hepatoprotectives were initiated. Causality assessment using Naranjo 
probability scale indicated a probable relationship (score-7) between the patient’s condition and the use of VPA. Clinicians prescribing VPA should 
go for careful liver function monitoring not only initially but throughout the time the drug is given. 
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INTRODUCTION 
Valproic acid (VPA) is a branched chain carboxylic acid that is 
mainly used in the treatment of epilepsy and bipolar disorder. It is a 
broad-spectrum antiepileptic agent used in the treatment of 
absence, myoclonic, partial and tonic-clonic seizures [1]. It is also 
used to prevent migraine headaches. VPA acts by increasing the 
availability of gamma amino butyric acid (GABA), an inhibitory 
neurotransmitter, to brain neurons or may enhance the action of 
GABA or mimic its action at postsynaptic receptor sites [2].  
The most common side effects of VPA are transient gastrointestinal 
side effects including anorexia, nausea and vomiting in 
approximately 16% of patients [3]. VPA toxicity has been steadily 
increasing in frequency since the FDA approved the drug in 1995 for 
acute mania. According to the 2008 Annual Report of the American 
Association of Poison Control Centres’ National Poison Data Systems 
(NPDS), 8,705 acute exposures to VPA occurred. Of these cases, 
major adverse outcomes were reported in 404 patients of this 
cohort [4].  
Hepatotoxicity due to VPA appears in two forms. The benign form 
exists as a mild, dose-related elevation of liver enzymes [5, 6] that 
appears with reduction in dosage or discontinuation of the drug. The 
other form is a less common non-dose related disorder 
characterized by hepatic failure [7, 8]. The mechanism of valproate 
hepatotoxicity is thought to be due to mitochondrial toxicity, may be 
from inhibition of beta-oxidation and subsequent loss of 
mitochondrial function. 
Here we will be discussing a case of Drug-Induced Transaminitis. 
Transaminitis is one of the earlier signs of hepatotoxicity. 
Transaminitis is the elevation of transaminases in the liver, most 
commonly alanine transaminases and aspartate transaminases. 
These enzymes are normally present in high concentrations within 
the hepatocytes. The presence of elevated serum concentrations of 
one or more of these enzymes suggests hepatocytes have lysed in 
response to some noxious insult, resulting the cell contents to 
circulate in the blood. [9] Other causes of transaminitis include 
alcoholic liver disease, viral hepatitis and hemochromatosis. In the 
case of drug-induced transaminitis, the levels of transaminases 
usually come down after the offending drug is stopped. Other 
measures include administration of IV Carnitine and addition of 
hepato protective’s [10]. 
CASE REPORT 
A 21 y old female patient was admitted in our hospital due to 
complaints of high-grade intermittent fever and vomiting episodes 
after consuming food from outside 2 d prior to hospital admission. 
The patient had nausea and multiple episodes of vomiting associated 
with food particles. The patient is a known case of seizure disorder 
on antiepileptics since 3 y. She had 3 episodes of seizure in the past 
3 y. She was treated with Tab. Sodium Valproate 200 mg 1-0-1. She 
was seizure free for the past 1 y. 
On examination, the patient was hypotensive. Physical examination 
revealed icterus was present and right lumbar tenderness was also 
present. On admission, her routine laboratory investigations were 
performed that revealed transaminitis. The Aspartate 
aminotransferase (AST) was 7139 IU/l (normal: 5-35 IU/l) and 
Alanine aminotransferases (ALT) level was 7006 IU/l (normal: 5-45 
IU/l). She also had an elevated INR value of 2.31. USG abdomen was 
performed that turned out to be normal. Causality assessment using 
Naranjo probability scale indicated a probable (score-7) relationship 
between the patient’s condition and the use of VPA. 
The case was diagnosed to be Drug Induced Transaminitis. After 
neurologist’s consultation, tab sodium valproate was stopped on the 
first day of admission itself and Inj. Levipil (levetiracetam) IV 500 
mg 1-0-1 was started. After stopping the drug, the AST and ALT 
levels were as follows: 
  
Table 1: .Laboratory investigations during hospital stay 
Test 1/5/2015 (Day of admission) 2/5/15 3/5/15 4/5/15 5/5/15 Normal level 
AST 
7136  2289  604  275  99  
5-35 IU/l 
ALT 
7006  4278  2227  1712  1133.5  
5-45IU/l 
The patient was also observed to have deranged International Normalized Ratio (INR) level. Vitamin K injection was administered to correct the 
INR levels. After the injection the INR level came down within the normal range. 
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Table 2: INR Levels during hospital stay 
Test 1/5/2015 (Day of admission) 2/5/2015 3/5/15 4/5/15 5/5/15 Normal level 
INR 
2.31  2.39  
1.14 1.04 1.31 0.9-1.2 
 
She responded to the above-mentioned treatment and remained 
asymptomatic. At the time of discharge, her issues were resolved, 
transaminitis subsided and INR was normalized. The patient was 
discharged on Tab Levipil (Levetiracetam) 500 mg 1-0-1 and other 
hepatoprotectives like Tab. Udiliv (ursodeoxycholic acid) 300 mg 1-0-1, 
Tab Heptral (ademetionine) 400 mg 1-0-1, Tab. Silymarin 140 mg 1-0-1, 
Tab. Rifagut (rifaximin) 400 mg 1-1-1.   
The patient came on 22/5/2015 for follow-up, during which her lab 
investigations showed the following results: 
  
Table 3: Laboratory investigations during follow-up 
Test Result Normal level 
AST 25.3 IU/l 5-35 IU/l 
ALT 41.3 IU/l 5-45 IU/l 
INR 0.91 0.9-1.2 
 
DISCUSSION 
VPA is said to be an effective and popular antiepileptic agent which 
is associated with only a very small number of patients who have 
had severe toxic effects from its use. In up to 44% of patients chronic 
dosing with VPA may be associated with elevations in the 
transaminases during the first months of therapy. [11] Prospective 
studies suggest that 5%-10% of persons develop ALT elevations 
during long term valproate therapy, but it has been said that these 
abnormalities are usually asymptomatic and can resolve even with 
continuation of the drug. Although the overall incidence is estimated 
at 1 in 5000 to 1 in 50000, the occurrence of fatal hepatotoxicity can 
be as high as 1 in 800 in high risk groups.  
The various measures of management include  
 Discontinuation of the possible offending drug 
 Close laboratory monitoring 
 Specific therapy may not be available, and most of the time, 
management is supportive. 
 Liver biopsy may be helpful in excluding other causes of liver injury 
 Addition of hepatoprotectives 
In a study conducted by Koeing S A et al. in Germany from 1994 to 
2003 reports that of the published cases of fatalities with sodium 
valproate, 61% occurred within the first 3 mo of valproic acid 
treatment, with the appearance of first symptoms between 4 w and 
3 mo after starting valproic acid. In these patients, the hepatotoxicity 
was resolved after discontinuation of the drug and addition of IV 
carnitine supplementation [12]. In another study conducted by Ware 
S and Sadler G H M on five patients who developed the acute liver 
disease after treatment with sodium valproate reports that the liver 
disease began 3-6 mo after the start of treatment [13]. 
In contrast, in our case, the patient has developed transaminitis after 
3 y of treatment with VPA. The drug was stopped as soon as an 
elevation in transaminases was observed. Currently, the patient has 
been put on Levetiracetam 500 mg as a replacement for VPA. The 
levels of transaminases started to decrease immediately as VPA was 
stopped. The patient was also given hepatoprotective like Tab. Udiliv 
(ursodeoxycholic acid) 300 mg 1-0-1, Tab. Heptral (ademetionine) 
400 mg 1-0-1, Tab. Silymarin 140 mg 1-0-1, Tab. Rifagut (rifaximin) 
400 mg 1-1-1. Vitamin K injection was given in view of deranged INR 
values after which the INR levels came down to normal levels. 
CONCLUSION 
Although sodium valproate is an effective antiepileptic agent, 
hepatotoxicity continues to be an important and severe side effect of 
VPA therapy.  
Previously case reports have shown valproic acid-induced 
transaminitis which occurred in the initial months of initiation of 
therapy. But in this case, we have seen transaminitis that occurred 
after 3 y of therapy. In conclusion, physicians prescribing VPA 
should go for careful liver function monitoring not only initially but 
throughout the time the drug is given. 
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